RU2013106217A - HYBRID PROTEIN FROM ANTIBODIES AGAINST MHC AND ANTIVIRAL CYTOKINE - Google Patents
HYBRID PROTEIN FROM ANTIBODIES AGAINST MHC AND ANTIVIRAL CYTOKINE Download PDFInfo
- Publication number
- RU2013106217A RU2013106217A RU2013106217/10A RU2013106217A RU2013106217A RU 2013106217 A RU2013106217 A RU 2013106217A RU 2013106217/10 A RU2013106217/10 A RU 2013106217/10A RU 2013106217 A RU2013106217 A RU 2013106217A RU 2013106217 A RU2013106217 A RU 2013106217A
- Authority
- RU
- Russia
- Prior art keywords
- fusion protein
- seq
- amino acid
- acid sequence
- protein according
- Prior art date
Links
- 108090000695 Cytokines Proteins 0.000 title claims abstract 9
- 102000004127 Cytokines Human genes 0.000 title claims abstract 9
- 230000000840 anti-viral effect Effects 0.000 title claims abstract 9
- 102000004169 proteins and genes Human genes 0.000 title claims abstract 7
- 108090000623 proteins and genes Proteins 0.000 title claims abstract 7
- 108020001507 fusion proteins Proteins 0.000 claims abstract 43
- 102000037865 fusion proteins Human genes 0.000 claims abstract 43
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 33
- 208000002672 hepatitis B Diseases 0.000 claims abstract 11
- 241000700721 Hepatitis B virus Species 0.000 claims abstract 8
- 108010033276 Peptide Fragments Proteins 0.000 claims abstract 6
- 102000007079 Peptide Fragments Human genes 0.000 claims abstract 6
- 210000003494 hepatocyte Anatomy 0.000 claims abstract 6
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims abstract 4
- 125000000539 amino acid group Chemical group 0.000 claims abstract 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims abstract 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract 2
- 239000000427 antigen Substances 0.000 claims abstract 2
- 108091007433 antigens Proteins 0.000 claims abstract 2
- 102000036639 antigens Human genes 0.000 claims abstract 2
- 210000004027 cell Anatomy 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 238000012258 culturing Methods 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 102000002227 Interferon Type I Human genes 0.000 claims 1
- 108010014726 Interferon Type I Proteins 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 229940047124 interferons Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1. Слитый белок, содержащий антитело, которое специфически связывается с главным комплексом гистосовместимости человека, презентирующим пептидный фрагмент белка вируса гепатита B, и антивирусный цитокин.2. Слитый белок по п.1, отличающийся тем, что пептидный фрагмент белка вируса гепатита B имеет аминокислотную последовательность, соответствующую аминокислотным остаткам 182-190 последовательности SEQ ID NO: 01 или аминокислотным остаткам 18-27 последовательности SEQ ID NO: 02.3. Слитый белок по п.1, отличающийся тем, что антитело специфически связывается с гепатоцитами, инфицированными вирусом гепатита B.4. Слитый белок по п.1, отличающийся тем, что антивирусный цитокин выбран из интерферонов типа I и(или) II.5. Слитый белок по п.1, отличающийся тем, что слитый белок обладает такой же специфичностью, как T-клетки, несущие CD8.6. Слитый белок по п.1, отличающийся тем, что антитело не обладает способностью к специфическому связыванию с антигенами вируса сывороточного гепатита B.7. Слитый белок по п.1, отличающийся тем, что антитело представляет собой моноклональное антитело.8. Слитый белок по п.1, отличающийся тем, что антитело представляет собой человеческое, гуманизированное или химерное антитело.9. Слитый белок по п.1, отличающийся тем, что антитело представляет собой фрагмент антитела, который специфически связывается с главным комплексом гистосовместимости человека, презентирующим пептидный фрагмент белка вируса гепатита B.10. Слитый белок по п.1, отличающийся тем, что антитело содержит:a) CDR-H3, содержащую аминокислотную последовательность SEQ ID NO: 06,b) CDR-L3, содержащую аминокислотную последовательность SEQ ID NO: 10 иc) CDR-H2, содержащую аминокислотн�1. A fusion protein containing an antibody that specifically binds to the main human histocompatibility complex, presenting a peptide fragment of the hepatitis B virus protein, and an antiviral cytokine. The fusion protein according to claim 1, characterized in that the peptide fragment of the hepatitis B virus protein has an amino acid sequence corresponding to amino acid residues 182-190 of the sequence SEQ ID NO: 01 or amino acid residues 18-27 of the sequence SEQ ID NO: 02.3. The fusion protein according to claim 1, characterized in that the antibody specifically binds to hepatocytes infected with hepatitis B virus. The fusion protein according to claim 1, characterized in that the antiviral cytokine is selected from interferons of type I and (or) II.5. The fusion protein according to claim 1, characterized in that the fusion protein has the same specificity as T cells carrying CD8.6. The fusion protein according to claim 1, characterized in that the antibody does not have the ability to specifically bind to serum hepatitis B.7 antigens. The fusion protein of claim 1, wherein the antibody is a monoclonal antibody. The fusion protein according to claim 1, characterized in that the antibody is a human, humanized or chimeric antibody. The fusion protein according to claim 1, characterized in that the antibody is an antibody fragment that specifically binds to the main histocompatibility complex of a person presenting a peptide fragment of the hepatitis B virus protein. The fusion protein according to claim 1, characterized in that the antibody contains: a) CDR-H3 containing the amino acid sequence of SEQ ID NO: 06, b) CDR-L3 containing the amino acid sequence of SEQ ID NO: 10 and c) CDR-H2, containing amino acid
Claims (35)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10172054 | 2010-08-05 | ||
EP10172054.8 | 2010-08-05 | ||
EP10191498.4 | 2010-11-17 | ||
EP10191498 | 2010-11-17 | ||
PCT/EP2011/063362 WO2012017003A1 (en) | 2010-08-05 | 2011-08-03 | Anti-mhc antibody anti-viral cytokine fusion protein |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2013106217A true RU2013106217A (en) | 2014-09-10 |
Family
ID=45558957
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2013106217/10A RU2013106217A (en) | 2010-08-05 | 2011-08-03 | HYBRID PROTEIN FROM ANTIBODIES AGAINST MHC AND ANTIVIRAL CYTOKINE |
Country Status (10)
Country | Link |
---|---|
US (1) | US20130266565A1 (en) |
EP (1) | EP2600898A1 (en) |
JP (1) | JP2013541937A (en) |
KR (1) | KR20130049196A (en) |
CN (1) | CN103209709A (en) |
BR (1) | BR112013002532A2 (en) |
CA (1) | CA2805564A1 (en) |
MX (1) | MX2013001305A (en) |
RU (1) | RU2013106217A (en) |
WO (1) | WO2012017003A1 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10201601882PA (en) * | 2011-12-22 | 2016-04-28 | Hoffmann La Roche | Expression Vector Organization, Novel Production Cell Generation Methods And Their Use For The Recombinant Production Of Polypeptides |
WO2013165972A2 (en) * | 2012-04-30 | 2013-11-07 | Cell Signaling Technology, Inc. | Anti-hepatitis b virus antibodies and use thereof |
EP2925779A1 (en) * | 2012-11-30 | 2015-10-07 | Institut Pasteur | Use of anti-fcyri and/or anti-fcyriia antibodies for treating arthritis, inflammation, thrombocytopenia and allergic shock |
AU2014259719B2 (en) | 2013-05-02 | 2019-10-03 | Anaptysbio, Inc. | Antibodies directed against programmed death-1 (PD-1) |
CN106349391A (en) * | 2015-07-17 | 2017-01-25 | 中国科学院深圳先进技术研究院 | HBV specific double-targeted antibody as well as preparation method and application thereof, minicircle DNA containing double-targeted antibody expression box and application of minicircle DNA |
EP3534950A4 (en) | 2016-11-01 | 2020-05-06 | AnaptysBio, Inc. | Antibodies directed against programmed death- 1 (pd-1) |
PT3565844T (en) | 2017-01-09 | 2023-05-02 | Tesaro Inc | Methods of treating cancer with anti-pd-1 antibodies |
EP3573997A4 (en) * | 2017-01-24 | 2020-12-09 | Abexxa Biologics, Inc. | Methods and compositions for targeting a complex comprising non-classical hla-i and neoantigen in cancer |
KR20200010217A (en) * | 2017-04-07 | 2020-01-30 | 시아먼 유니버시티 | Antibodies for the treatment of hepatitis B infections and related diseases |
EP3692072A4 (en) * | 2017-10-03 | 2021-12-22 | Chugai Seiyaku Kabushiki Kaisha | Anti-hla-dq2.5 antibody |
GB201904328D0 (en) * | 2019-03-28 | 2019-05-15 | Immunocore Ltd | Specific binding molecules |
KR20220109436A (en) * | 2019-12-03 | 2022-08-04 | 에보텍 인터내셔널 게엠베하 | Interferon-conjugated antigen binding proteins and uses thereof |
CN116096757B (en) | 2020-09-18 | 2024-01-12 | 中外制药株式会社 | anti-HLA-DQ 2.5 antibodies and their use in the treatment of celiac disease |
Family Cites Families (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
ES2052027T5 (en) | 1988-11-11 | 2005-04-16 | Medical Research Council | IMMUNOGLOBULINE VARIABLE DOMAIN SEQUENCE CLONING. |
DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
EP0861893A3 (en) | 1991-09-19 | 1999-11-10 | Genentech, Inc. | High level expression of immunoglobulin polypeptides |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
JPH08511420A (en) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | Body |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
TW517067B (en) | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
ATE296315T1 (en) | 1997-06-24 | 2005-06-15 | Genentech Inc | COMPOSITIONS CONTAINING GALACTOSYLATED GLYCOPROTEINS AND METHOD FOR THE PRODUCTION THEREOF |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
ATE419009T1 (en) | 1997-10-31 | 2009-01-15 | Genentech Inc | METHODS AND COMPOSITIONS CONSISTING OF GLYCOPROTEIN GLYCOFORMS |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
DK1034298T3 (en) | 1997-12-05 | 2012-01-30 | Scripps Research Inst | Humanization of murine antibody |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
EP1068241B1 (en) | 1998-04-02 | 2007-10-10 | Genentech, Inc. | Antibody variants and fragments thereof |
PT1071700E (en) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
KR100940380B1 (en) | 1999-01-15 | 2010-02-02 | 제넨테크, 인크. | Polypeptide Variants with Altered Effector Function |
ES2571230T3 (en) | 1999-04-09 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedure to control the activity of an immunofunctional molecule |
KR100797667B1 (en) | 1999-10-04 | 2008-01-23 | 메디카고 인코포레이티드 | Method for regulating transcription of foreign genes |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
JP4668498B2 (en) | 1999-10-19 | 2011-04-13 | 協和発酵キリン株式会社 | Method for producing polypeptide |
US20030180714A1 (en) | 1999-12-15 | 2003-09-25 | Genentech, Inc. | Shotgun scanning |
NZ521540A (en) | 2000-04-11 | 2004-09-24 | Genentech Inc | Multivalent antibodies and uses therefor |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
CN102311986B (en) | 2000-10-06 | 2015-08-19 | 协和发酵麒麟株式会社 | Produce the cell of antibody compositions |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
ES2405944T3 (en) | 2000-11-30 | 2013-06-04 | Medarex, Inc. | Nucleic acids encoding reorganized human immunoglobulin sequences from transgenic transchromosomal mice zadas |
CA2838062C (en) | 2001-08-03 | 2015-12-22 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
AU2002337935B2 (en) | 2001-10-25 | 2008-05-01 | Genentech, Inc. | Glycoprotein compositions |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
AU2003236018A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa |
CN102911987B (en) | 2002-04-09 | 2015-09-30 | 协和发酵麒麟株式会社 | The adorned cell of genome |
JPWO2003084569A1 (en) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | Antibody composition-containing medicine |
AU2003236020B2 (en) | 2002-04-09 | 2009-03-19 | Kyowa Hakko Kirin Co., Ltd. | Cell with depression or deletion of the activity of protein participating in GDP-fucose transport |
WO2003085118A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing antibody composition |
US20050031613A1 (en) | 2002-04-09 | 2005-02-10 | Kazuyasu Nakamura | Therapeutic agent for patients having human FcgammaRIIIa |
NZ556507A (en) | 2002-06-03 | 2010-03-26 | Genentech Inc | Synthetic antibody phage libraries |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
BRPI0316779B1 (en) | 2002-12-16 | 2020-04-28 | Genentech Inc | humanized antibody that binds human cd20, composition, manufactured article, apoptosis induction method, cd20 positive cancer treatment method, autoimmune disease treatment methods, isolated nucleic acids, expression vectors, host cells, method for producing a humanized 2h7 antibody, isolated polypeptide, liquid formulation, method of treating rheumatoid arthritis (ra) and humanized cd20 binding antibodies |
WO2004065416A2 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
US7579157B2 (en) * | 2003-07-10 | 2009-08-25 | Hoffmann-La Roche Inc. | Antibody selection method against IGF-IR |
AU2004279742A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Fused protein composition |
CA2542125A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase |
RS58420B1 (en) | 2003-11-05 | 2019-04-30 | Roche Glycart Ag | Cd20 antibodies with increased fc receptor binding affinity and effector function |
JPWO2005053742A1 (en) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | Medicament containing antibody composition |
WO2005077980A2 (en) | 2004-02-13 | 2005-08-25 | Bioceros Bv | Soluble tcr-like molecules and their uses |
WO2005097832A2 (en) | 2004-03-31 | 2005-10-20 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
PL1737891T3 (en) | 2004-04-13 | 2013-08-30 | Hoffmann La Roche | Anti-p-selectin antibodies |
TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
JO3000B1 (en) | 2004-10-20 | 2016-09-05 | Genentech Inc | Antibody Formulations. |
EP2465870A1 (en) | 2005-11-07 | 2012-06-20 | Genentech, Inc. | Binding polypeptides with diversified and consensus VH/VL hypervariable sequences |
US20070237764A1 (en) | 2005-12-02 | 2007-10-11 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
WO2007134050A2 (en) | 2006-05-09 | 2007-11-22 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
WO2008027236A2 (en) | 2006-08-30 | 2008-03-06 | Genentech, Inc. | Multispecific antibodies |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
CN100592373C (en) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | Liquid crystal panel drive device and its drive method |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
SI2235064T1 (en) | 2008-01-07 | 2016-04-29 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
ES2622505T3 (en) * | 2008-05-09 | 2017-07-06 | Agency For Science, Technology And Research | Exogenous T lymphocyte receptor (RLT) reactive against HBV epitope and uses thereof |
BRPI1014089A2 (en) | 2009-04-02 | 2016-04-19 | Roche Glycart Ag | multispecific antibodies comprising full length antibodies and single chain fab fragments |
JP5616428B2 (en) | 2009-04-07 | 2014-10-29 | ロシュ グリクアート アクチェンゲゼルシャフト | Trivalent bispecific antibody |
SG176219A1 (en) | 2009-05-27 | 2011-12-29 | Hoffmann La Roche | Tri- or tetraspecific antibodies |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
US8703132B2 (en) | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
-
2011
- 2011-08-03 JP JP2013522240A patent/JP2013541937A/en active Pending
- 2011-08-03 KR KR1020137002652A patent/KR20130049196A/en not_active Application Discontinuation
- 2011-08-03 WO PCT/EP2011/063362 patent/WO2012017003A1/en active Application Filing
- 2011-08-03 RU RU2013106217/10A patent/RU2013106217A/en not_active Application Discontinuation
- 2011-08-03 BR BR112013002532A patent/BR112013002532A2/en not_active Application Discontinuation
- 2011-08-03 CA CA2805564A patent/CA2805564A1/en not_active Abandoned
- 2011-08-03 CN CN2011800386533A patent/CN103209709A/en active Pending
- 2011-08-03 EP EP11738740.7A patent/EP2600898A1/en not_active Withdrawn
- 2011-08-03 MX MX2013001305A patent/MX2013001305A/en not_active Application Discontinuation
-
2013
- 2013-02-04 US US13/758,788 patent/US20130266565A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2013541937A (en) | 2013-11-21 |
BR112013002532A2 (en) | 2016-05-31 |
CN103209709A (en) | 2013-07-17 |
WO2012017003A1 (en) | 2012-02-09 |
MX2013001305A (en) | 2013-03-20 |
CA2805564A1 (en) | 2012-02-09 |
EP2600898A1 (en) | 2013-06-12 |
KR20130049196A (en) | 2013-05-13 |
US20130266565A1 (en) | 2013-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2013106217A (en) | HYBRID PROTEIN FROM ANTIBODIES AGAINST MHC AND ANTIVIRAL CYTOKINE | |
JP7379561B2 (en) | Chimeric antigens and T cell receptors and methods of use | |
JP7425604B2 (en) | Anti-CTLA4-anti-PD-1 bifunctional antibodies, pharmaceutical compositions and uses thereof | |
US10689450B2 (en) | BCMA binding molecules and methods of use thereof | |
JP6949030B2 (en) | Treatment of CEA-Positive Cancer Using PD-1 Axial Binding Antagonists and Anti-CEA / Anti-CD3 Bispecific Antibodies | |
AU2014337367B2 (en) | Peptidic chimeric antigen receptor T cell switches and uses thereof | |
JP2023100964A (en) | Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereof | |
HRP20210876T1 (en) | Anti-tmprss2 antibodies and antigen-binding fragments | |
BR112020007002A2 (en) | anti-cd38 antibodies and methods of use | |
IL274595B2 (en) | Antibodies specific for tgf-beta | |
RU2019134352A (en) | NEW BISPECIFIC ANTIGEN-BINDING MOLECULES WITH THE ABILITY TO BIND SPECIFICALLY WITH CD40 AND FAP | |
JP2018537962A5 (en) | ||
CN106519034A (en) | Anti-PD-1 (Programmed Death-1) antibody and application thereof | |
CN111511764A (en) | CLEC9A binding agents and uses thereof | |
TW202140567A (en) | Chimeric antigen and t cell receptors and methods of use | |
WO2016154621A1 (en) | SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF | |
HRP20220637T1 (en) | Anti-complement c1s antibodies and uses thereof | |
US20230293652A1 (en) | Immunostimulatory adjuvants | |
JP6563389B2 (en) | IL-21 binding protein and use thereof | |
JP2019537449A5 (en) | ||
JP2022527506A (en) | Recombinant protein with CD40 activation properties | |
CN116323667A (en) | Antibodies that bind PSMA and gamma-delta T cell receptors | |
JP2022553129A (en) | Antibodies against poliovirus receptor (PVR) and uses thereof | |
US20220396623A1 (en) | Uses of anti-icos antibodies | |
CN117940461A (en) | Bispecific antibody and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20140804 |